Keay Nakae

In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX), and raised the price target from $23.00 to $25.00. In the report, Ascendiant Capital Markets noted, “We believe that the positive result from the ZA-305 study...

In a report published Friday, Ascendiant Capital Markets analyst Keay Nakae upgraded the rating on Pozen (NASDAQ: POZN) from Hold to Buy, and named a $10.00 price target. In the report, Ascendiant Capital Markets noted, “Pozen has reported Q2 results. Revenue was $7.4 MM compared to consensus of $7...

In a report published Wednesday, Ascendiant Capital Markets analyst Keay Nakae initiated coverage on Alliqua (NASDAQ: ALQA) with a Buy rating and $9.00 price target. In the report, Ascendiant Capital Markets noted, “We are initiating coverage of ALQA with a BUY rating and 12-month price target of $...

In a report published Thursday, Ascendiant Capital Markets analyst Keay Nakae downgraded the rating on PhotoMedex (NASDAQ: PHMD) from Buy to Hold, and removed the $18.00 price target. In the report, Ascendiant Capital Markets noted, “The acquisition of LCA Vision has now been completed. The...

In a report published Thursday, Ascendiant Capital Markets analyst Keay Nakae downgraded the rating on Repros Therapeutics (NASDAQ: RPRX) from Strong Buy to Buy, but reiterated the $25.00 price target. In the report, Ascendiant Capital Markets noted, “Yesterday, the company announced that the FDA...

In a report published Monday, Ascendiant Capital Markets analyst Keay Nakae initiated coverage on Galectin Therapeutics (NASDAQ: GALT) with a Buy rating and $13.00 price target. In the report, Ascendiant Capital Markets noted, “We are initiating coverage of GALT with a Buy rating and 12-month...